Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study

Not yet recruitingOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Leukemia, Lymphocytic, Acute, Adult
Interventions
DRUG

Blinatumomab

The 14-day blinatumomab combined with reduced-dose chemotherapy is used for the induction treatment of newly diagnosed Ph-chromosome negative acute B-lymphoblastic leukemia.

All Listed Sponsors
collaborator

Shandong Provincial Hospital

OTHER_GOV

collaborator

The Affiliated Hospital of Qingdao University

OTHER

collaborator

Tangshan Central Hospital

OTHER

collaborator

Affiliated Central Hospital of Shandong First Medical University

UNKNOWN

collaborator

Yantai Yuhuangding Hospital

OTHER

collaborator

Qilu Hospital of Shandong University (Qingdao)

OTHER

collaborator

Qingdao Central Hospital

OTHER

collaborator

Qingdao Municipal Hospital

OTHER

collaborator

The Affiliated Hospital of Jining Medical University and Zaozhuang City

UNKNOWN

collaborator

Affiliated Hospital of Binzhou Medical College

UNKNOWN

collaborator

Linyi People's Hospital

OTHER

collaborator

The Second Hospital of Shandong University

OTHER

collaborator

Affiliated Hospital of Shandong University of Traditional Chinese Medicine

OTHER

collaborator

Shandong First Medical University

OTHER

collaborator

Shengli Oilfield Hospital

OTHER

collaborator

Heze Municipal Hospital

OTHER

collaborator

Zibo Central Hospital

OTHER_GOV

collaborator

Zaozhuang Municipal Hospital

OTHER

collaborator

Weihai Municipal Hospital

OTHER

lead

Shandong University

OTHER